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ABSTRACT
Introduction: Hydroxychloroquine (HCQ),
4-aminoquinoline, is an antimalarial drug and
has become a basic therapy for rheumatic
disease treatment. It can stabilize the
condition of SLE patients and reduce the
chances of patient relapse through its
immunosuppressive function and
antiinflammatory effects. This drug was
absorbed completely and rapidly by oral
administration, but has a prolonged half-life
for elimination. The objective of this study was
to evaluate the pharmacokinetic parameters
and relative bioequivalence of a new generic
(test) formulation with the branded (reference)
formulation of HCQ in healthy Chinese male
volunteers. This study was designed to acquire
regulatory approval for the test formulation.
Methods: This study was conducted with a
randomized, single-dose, two-period, and
crossover design. The male subjects were
randomly assigned to two groups at a 1:1 ratio
to receive 0.2 g hydroxychloroquine sulfate
tablets (0.1 g/piece) of the two formulations
after a 3-month washout period then
administered the alternate formulation. Study
drugs were administered after overnight fasting
(over 10 h). Plasma concentrations of
hydroxychloroquine were measured by a
validated LC-MS/MS method. The following
pharmacokinetic properties were determined
by a noncompartmental pharmacokinetic
method: Cmax, Tmax, AUC0–t, AUC0–, and t1/2.
The bioequivalence between the test and
reference products was assessed based on the
following parameters: Cmax, AUC0–60d, and
AUC0– using the ANOVA method. If the 90%
CI for AUC0–t was within 80–125% and for Cmax
was within 70–143% of the statistical interval
proposed by the SFDA, the two formulations
were assumed bioequivalent. Concerning the
main pharmacokinetic charateristics of
hydroxychloroquine, a long half-life drug, the
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pharmacokinetic parameters of 0–72 h were
determined according to the FDA.
Furthermore, a comparison was made between
the parameters at 0–60 days and 0–72 h to
evaluate whether a truncated AUC method can
be applied to estimate the relative
bioavailability of HCQ. Tolerability was
assessed by monitoring vital signs and
laboratory tests and by questioning subjects
about adverse events.
Results: The 90% CI of Cmax for HCQ is
103.8–142.3%; the AUC0–60 is 100–114.2%
and AUC0– 100–115.5%. Both met the criteria
according to the SFDA’s guidelines for
bioequivalence. The relative bioavailability was
109.5% (according to AUC0–60d) and 110.7%
(according to AUC0–). No serious or
unexpected adverse events were observed.
Conclusions: In this study, the
pharmacokinetic studies and results were
conducted so that the test and reference
formulations of HCQ met the Chinese criteria
for assuming bioequivalence. Both formulations




Hydroxychloroquine (HCQ) is a
4-aminoquinoline that differs from
chloroquine (CQ) by the addition of a
hydroxyl group. It was first synthesized in
1944 and initially used as an antimalarial
agent [1]. The activity of HCQ against malaria
is equivalent to that of CQ, and HCQ is
preferred over CQ when high doses are
required because of its lower level of ocular
toxicity [2]. Both drugs have now become
mainstays in the management of rheumatic
diseases: principally systemic lupus
erythematosus (SLE) and rheumatoid arthritis
(RA) [3, 4]. Now HCQ is considered the second-
line treatment for SLE, but it is quite effective
therapeutically. One study showed that HCQ
can reduce the risk of clinical SLE flares and
severe SLE exacerbations [5]. Insulin resistance
occurs more frequently in RA and SLE and is a
common risk factor for cardiovascular disease
(CVD) and diabetes mellitus (DM) [6–8]. A study
showed that HCQ has a beneficial effect on
insulin sensitization by using HCQ in non-
diabetic obese subjects for 6 weeks [9]. HCQ also
appears to protect against the occurrence of
thrombotic events [10]. In addition, the main
mechanism of HCQ applied in rheumatic
diseases is the inhibition of stimulation of
Toll-like receptors (TLRs). TLRs are cellular
receptors for microbial products that induce
inflammatory responses by activating the
innate immune system [11]. Two types of side
effects may be encountered with HCQ
treatment: one is gastrointestinal intolerance,
which usually disappears with dose reduction;
the other is rare but potentially severe and
involves various combinations of retinal,
neuromuscular, cardiac, and hematological
impairments. Compared with CQ treatment,
retinopathy’s incidence in HCQ treatment is
very small [12].
HCQ is rapidly and almost completely
absorbed after oral administration (the
absorption rate through the gastrointestinal
tract is 70–80%). However, it has a prolonged
half-life (between 40 and 50 days) and low
blood clearance (96 ml/min) because of its PK
properties [13]. Approximately 50% of the HCQ
in plasma is bound to plasma proteins. In the
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Although the pharmacokinetic properties of
HCQ have been well identified in previous
studies, few studies have been conducted on
the PK characteristics of HCQ among healthy
Chinese individuals. Although one similar study
reported on the bioequivalence of HCQ, it had a
parallel study design. However, according to the
findings of Tett et al. [16], the bioavailability of
HCQ is consistent in each individual at different
times but variable between subjects. The FDA
also advises that a crossover study design can
make the variables determined by physiological
factors (such as the clearance, volume of
distribution, and absorption) have less
interoccasion variability than that arising from
formulation performance. Therefore, differences
between two products because of formulation
factors can be determined [17]. Thus, this study
was conducted using a crossover design.
Compared with the preceding study design,
this one could eliminate individual differences.
Before a generic product can be marketed in
China, the State Food and Drug Administration
(SFDA) requires a bioequivalence experiment.
The aim of this study was to compare the relative
bioavailability of a new generic formulation
(test) of HCQ and the branded formulation
(reference) in a Chinese population to meet
the SFDA’s requirement for marketing the
generic formulation in China.
METHODS
Materials
Hydroxychloroquine sulfate was purchased
from C & O Pharmaceutical Technology
(Holdings), Ltd., (Nanjing, China), lot no.
090526. Chloroquine phosphate was
purchased from The National Institute for the
Control of Pharmaceutical and Biological
Products, lot no. 100421-200401. The
reference formulation was obtained from
Shanghai Zhongxi Pharmaceutical Co., Ltd.,
Shanghai, China, lot no. 081203. The test
formulation was obtained from Jiangsu
Shenhua Pharmaceutical Co., Ltd., Jiangsu,
China, lot no. 20090721. HPLC grade
methanol, acetonitrile, and formic acid were
all purchased from Merck. Milli-Q deionized
water was used throughout the study.
Instruments
For analysis, a Shimadzu UFLC-20 AD XR liquid
system interfaced to an Applied Biosystems API-
5000 tandem quadrupole mass spectrometer
(analysis software Analyst 1.5) was equipped
with a 50 9 2.1-mm 2.6-lm C18 column
(Kinetex, Phenomenex) at room temperature.
Study Design and Procedures
Healthy Chinese males aged 18–40 years with
BMIs between 19 and 24 kg/m2 were enrolled in
the study. Subjects were considered healthy on
the basis of medical history, full physical
examination, clinical laboratory tests
(especially for renal and hepatic function),
vital signs (oral body temperature, heart rate,
respiratory rate, and sitting blood press), and
12-lead ECGs. Subjects were excluded if they
had any impairment of a major organ; had used
or abused an illegal drug or alcohol; had
psoriasis, active bleeding, colds, or clinically
significant abnormalities or
hydroxychloroquine-like eye lesions after
inspection of the fundus; had a history of
mental or neurological disease or glucose-6-
phosphate dehydrogenase (G-6-PD) defects; had
an allergy or sensitivity to 4-aminoquinoline
compounds; or had participated in a clinical
trial within 2 weeks or donated blood within
2 months prior to the study. The subjects had
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been informed about the details, including the
risks and benefits of this study, and they were
free to withdraw at any time.
The study was conducted according to a
randomized, open-label, single-dose, two-
period, and crossover design. Subjects were
assigned randomly to two groups to receive a
single dose of 0.2 g hydroxychloroquine sulfate
tablets (0.1 g/piece) with 250 ml water in the
test formulation (Jiangsu Shenhua
Pharmaceutical Co., Ltd., Jiangsu, China; lot
no. 20090721) or the reference formulation
(Shanghai Zhongxi Pharmaceutical Co., Ltd.,
Shanghai, China; lot no. 081203). Subjects were
required to take tablets after overnight fasting
(over 10 h) and without breakfast, and they
were not allowed to drink alcohol, coffee, and
juice, but were allowed to drink water 2 h after
administration. They were allowed to have a
standard meal 4 h after administration. There
was a 3-month drug-free washout period
followed by administration of the initial
formulation after the alternate formulation
had been administered. At the end of the test,
subjects were scheduled to have re-
examinations of routine blood tests and
alanine aminotransferase, aspartate
aminotransferase, and creatinine levels.
Blood samples (3 ml each) were collected
from a suitable forearm vein by an indwelling
catheter at the following time points: before
dosing (baseline), 1, 2, 3, 4, 5, 7, 9, 12, 24, 48 h
(day 3), 72 h (day 4), 120 h (day 6), day 10, day
20, day 40, and day 60 after administration.
Blood samples were collected into tubes
containing sodium-heparin as anticoagulant
then immediately stored in a container filled
with ice. Samples were handled within 30 min
after collection. Plasma was stored frozen
(-65C) in labeled polypropylene tubes until
analysis.
Drug Assay
Stock and Working Solutions
Stock solutions of hydroxychloroquine and
chloroquine (Inner Standard, The National
Institute for the Control of Pharmaceutical
and Biological Products, Beijing, China; Lot
no.100421-200401) were prepared in water
(1 mg/ml) and further individually diluted
with water to obtain the desired
concentrations: hydroxychloroquine, 100 lg/
ml; chloroquine (IS), 10.0 lg/ml and 100 ng/
ml. The stock solutions were kept refrigerated
and restored to room temperature before use.
Calibration Standards and QC Samples
The standard curve ranged from 0.200 to
100 ng/ml (r = 0.9930). Eight calibration
standards were prepared according to the
preparation of stock solutions; their
concentrations were 0.200, 0.400, 2.00, 5.00,
10.0, 20.0, 50.0, and 100 ng/ml. There were
double samples at one concentration. The
quality control samples were prepared at
concentrations of 0.500 (low), 15.0 (medium),
and 80.0 ng/ml (high); six samples were
prepared at each concentration, as a single
batch at each concentration.
Sample Preparation
All frozen human plasma samples were first
restored to room temperature. A 50-ll volume
of plasma was transferred to a micro-centrifuge
tube (1.5 ml); 0.3 ml acetonitrile was added
sequentially and vortex-mixed for 3 min. After
centrifugation at 4000 rpm (4C) for 10 min,
150 ll supernatant was pipetted and dried by
nitrogen (35C), then reconstituted with 200 ll
20% methanol solution, vortexed, and
centrifuged at 4000 rpm for 5 min. The
supernatant was pipetted for assay.
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Chromatographic Conditions
The samples were injected onto a 50 9 2.1-mm
2.6-lm C18 column (Kinetex, Phenomenex) at
room temperature. The mobile phase comprised
0.6% formic acid aqueous solution (phase A)
and methyl alcohol (80:20, v/v) (phase B) at a
flow rate of 0.5 ml/min. The column
temperature was at room temperature.
Mass Spectrometric Conditions
The analytes were quantified by mass spectral
detection using a mass spectrometer (API 5000,
AB SCIEX) equipped with an Turbo-ESI source,
which runs in positive mode. The mass
spectrometer was set up in MRM mode to
monitor the transitions 336.2? 247.2 and
320.2? 247.2 for hydroxychloroquine sulfate
and IS, respectively. The capillary voltage was




Eight calibration standards were prepared
according with the preparation of stock
solutions; their concentrations were 0.200,
0.400, 2.00, 5.00, 10.0, 20.0, 50.0, and 100 ng/
ml. There were double samples at one
concentration. The standard curves were
calculated by the equation f = aC ? b using
weighted (1/C2) least square regression.
Lower Limit of Quantitation
Six copies of plasma containing standard
hydroxychloroquine at a concentration of
0.200 ng/ml were prepared and analyzed by
LC-MS/MS. According to the chromatograms,
the calculated f (the ratio of peak areas between
the hydroxychloroquine solution and internal
standard) was then substituted into the
standard curve obtained on that day to
determine the actual concentration.
Eventually, we calculated the accuracy and
RSD. The results suggested that the lower limit
of quantitation could meet the acceptance
criteria (Fig. 1).
Specificity
Six randomly selected control blank human
plasma samples were processed by a similar
extraction procedure and analyzed to determine
whether the hydroxychloroquine and
chloroquine peaks were well shaped and no
Fig. 1 Full-scan product ion spectra of a hydroxychloroquine sulfate and b chloroquine phosphate
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impurity peaks interfered with the
determination under the chromatographic
conditions used in this study. The results in
Fig. 2 suggest that the conditions provided high
specificity and sensitivity (Table 1) and can
accurately determine the concentration of
plasma hydroxychloroquine.
Recovery and Matrix Effect
The recovery was evaluated by the response of
the analyte recycled from the biological sample
matrix divided by the response of the pure
standard. The matrix effect experiments were
performed by evaluating the ratio between the
spiked mobile phase solutions and un-extracted
samples spiked on plasma residues (Table 2).
Accuracy and Precision
Both the accuracy and precision evaluations
were performed by repeated analysis of
hydroxychloroquine in human plasma. The
run consisted of a calibration curve and six
Fig. 2 a Hydroxychloroquine reference chromatogram;
b internal standard reference chromatogram; c blank
plasma chromatogram; d blank plasma plus hydroxychloro-
quine and internal standard reference chromatogram;
e plasma samples collected from healthy subjects taking
hydroxychloroquine sulfate tablets orally 200 mg after 1 h
chromatogram. Hydroxychloroquine (upper): m/z
336.2? 247.2; internal standard (lower): m/z
320.2? 247.2
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replicates each of LLOQ and the low-, medium-,
and high-quality control samples. Three batches
were measured respectively, recording the
chromatograms and then calculating f (the
ratio of peak areas between the
hydroxychloroquine solution and internal
standard), obtaining the accuracy of the
measured concentrations through the standard
curve. Eventually, we calculated the accuracy
values between and within batches. The
acceptance criterion for each batch was that
the deviation of the calculated concentrations
should be within ±15.0% of their theoretical
concentrations (±20.0% for lower limit of
quantification). The results shown in Table 3
indicate that the assay method is reproducible
for replicate analysis of hydroxychloroquine in
human plasma.
Stability
The stability of hydroxychloroquine in plasma
was evaluated in the following studies: a
stability study at room temperature, a stability
study in an auto-sampler, and a freeze-thaw
study. LLOQ and QC samples (0.500,
80.0 ng ml-1) of hydroxychloroquine were
assayed among three batches.
Fig. 2 continued
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Pharmacokinetic Analysis
Pharmacokinetic properties were determined by
a noncompartmental pharmacokinetic method.
The following parameters were calculated for
each subject during each session: Cmax, Tmax,
AUC0–t, AUC0-, and t1/2. Cmax and Tmax were
obtained directly from the plasma
concentration versus time curve. Other
parameters (AUC0–t, AUC0– and t1/2) were
calculated by noncompartmental analysis
using DAS version 2.0 (Shareware Software,
Shanghai, China). AUC0–t was calculated using
the trapezoidal method and AUC0– as AUC0–
t ? Ct/ke, where ke is the terminal elimination
rate constant calculated by linear least squares
regression analysis using the points in the
terminal log-linear phase from the plasma
concentration versus time curve. t1/2 represents
the apparent first-order terminal elimination
half-life, calculated as 0.693/ke. The relative
bioavailability (F) of the tested formulation was
calculated as AUC0–t (test)/AUC0–t
(reference) 9 100%.
The bioequivalence between the test and
reference products was assessed based on the
following parameters: Cmax, AUC0–60d, and
AUC0-. An ANOVA using DAS version 2.0 for
a double crossover experimental design was
used to compare the log-transformed Cmax,
AUC0–60d, and AUC0– values. Period,
subject, and sequence effects were determined
at a significance level of a = 0.05. The 90% CIs
served as interval estimates and were
determined using two one-sided t tests. If the
differences in PK parameters between the two
formulations were not statistically significant
(P[0.05) and the 90% CI for AUC0–t was within
80–125% and for Cmax was within 70–143% of
the statistical interval proposed by the SFDA,
then the two formulations were considered to
have met the regulatory requirements for
bioequivalence.
Tolerability
Throughout the study, subjects were monitored
by two doctors, two pharmacists, and two
nurses. Tolerability was assessed based on vital
signs (blood pressure, heart rate, breathing rate),
clinical laboratory tests, and 12-lead ECGs.
Physical examinations were performed at
baseline and after completion of the study;
subjects were interviewed about symptoms of
possible adverse events (AEs). Once any
undesirable symptoms occurred in subjects,
the information would be recorded on the
CRF, and the subjects would countinue to be




Twenty-one healthy Chinese male volunteers
participated in this study; 20 volunteers
eventually completed the study. The patient
Table 2 Extraction recovery and method recovery of







0.50 98.56 ± 6.87 91.87 ± 5.59
15.0 97.66 ± 5.43 98.22 ± 3.29
80.0 95.64 ± 5.77 97.84 ± 5.51
Table 3 Intra-group and inter-group precision of HCQ
assays in plasma (n = 6)
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characteristics [mean (SD)] were as follows: age,
weight, height, and body mass index
respectively were 22 [2.9] years, range 21 to
29 years; 69 [6.2] kg, range 54 to 75 kg; 174 [5.1]
cm, range 166 to 183 cm; 23 [1.3] kg m-2, range
19 to 24 kg m-2.
LC/MS/MS Method Validation
The linear range of hydroxychloroquine was
0.20–100 ng/ml (r = 0.9911). Moreover, the
accuracy of the range from 0.20 to 100 ng/ml
was between 87.60 and 104.13%, the inter-
analysis RSD was\6.0%, and the intra-analysis
RSD was\6.2%. For LLOQ, the accuracy ranged
from 88.00 to 97.50%. The matrix effect and
recovery [mean (SD)] of hydroxychloroquine
were 102.40 [2.18] and 98.23 [2.28]%; for IS
they were 99.08 [1.62] and 93.16 [5.87]%,
respectively.
Statistical Evaluation of Pharmacokinetic
Parameters
0–60d
The mean ± SD main pharmacokinetic
parameters Cmax (index of the rate of
absorption), AUC0–60d, and AUC0- of the
test and reference formulations (n = 20) are
shown in Table 4. The mean (SD)
concentration-time curves of HCQ after
administration of the two formulations are
shown in the Fig. 3. The 90% CIs of the ratios
(test:reference) for the log-transformed Cmax
and AUC0-60d were 103.8–142.3% and
100.0–114.2%, respectively. The relative
bioavailability was 109.5% (according to
AUC0–60d) and 110.7% (according to AUC0–).
0–72h
The mean ± SD main pharmacokinetic
parameters Cmax (index of the rate of
absorption), AUC0–72h, and AUC0– of the
test and reference formulations (n = 20) are
shown in Table 5. The mean (SD)
concentration-time curves of HCQ after
administration of the two formulations are
shown in the Fig. 4. The 90% CIs of the ratios
(test:reference) for the log-transformed Cmax
and AUC0–72h were 103.8–142.3% and
104.8–117.2%, respectively. The relative
bioavailability was 111.8% (according to
AUC0–72h) and 105.9% (according to AUC0–).
Both the mean values and standard
deviations of the main pharmacokinetic
parameters such as Cmax, Tmax, AUC0–60d, and
AUC0– were found to be close between the test
and reference preparations. In addition, the
calculated 90% confidence interval for mean
Cmax, AUC0–60d, and AUC0– of the two drugs
lay within the SFDA’s accepted range of
80–125%. Therefore, it could be concluded
that the two hydroxychloroquine preparations
analyzed were bioequivalent in terms of the rate
and extent of absorption.
Tolerability
No serious or unexpected adverse events were
observed.
DISCUSSION
The aim of this study was to compare the
bioavailability of the test formulation with that
of the reference formulation, intending to
acquire regulatory approval for the test
formulation of HCQ. In this study, the AUC0–t,
AUC0–, and Cmax of HCQ were defined as the
main parameters in order to assess the
bioequivalence between both preparations.
The criteria according to the SFDA’s guidelines
for bioequivalence are the 90% CIs of the test/
reference geometric means ratio in the range of
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80–125% for the AUC and 70–143% for Cmax
[15]. The ANOVA results of this study showed
that the formulation, period, and sequence had
no statistically significant effect on the AUC0–t,
AUC0–, and Cmax of HCQ. Chinese regulatory
authorities do not require the testing of food
effects in relative bioavailability studies.
Therefore, we only conducted this study under
the fasting condition.
In the bioequivalence study of HCQ sulfate
tablets (0–60 days), the ANOVA analysis results
suggested that the main pharmacokinetic
parameters are in accordance with the
pharmacokinetics characteristic of a long half-
life drug. As previously mentioned, the intra-







90% Conﬁdence limit (%)
Tmax (h) 3.65 ± 1.14 3.85 ± 1.04
Cmax (ng/ml) 34.3 ± 9.5 44.1 ± 27.6 103.8–142.3
AUC0–60d (ng h/ml) 1679 ± 385 1789 ± 383 100–114.2
AUC0–? (ng h/ml) 1819 ± 417 1950 ± 435 100–115.5
t1/2 (h) 272 ± 76 298 ± 105
Reference formulation: Shanghai Zhongxi Pharmaceutical Co., Ltd., Shanghai, China
Test formulation: Jiangsu Shenhua Pharmaceutical Co., Ltd., Jiangsu, China







90% Conﬁdence limit (%)
Tmax (h) 3.65 ± 1.14 3.85 ± 1.04
Cmax (ng/ml) 34.3 ± 9.5 44.1 ± 27.6 103.8–142.3
AUC0–72h (ng h/ml) 559 ± 94.1 617 ± 88.9 104.8–117.2
AUC0– (ng h/ml) 753 ± 251 749 ± 108 92.9–112.6
t1/2 (h) 34.0 ± 16.9 32.3 ± 14.1
Reference formulation: Shanghai Zhongxi Pharmaceutical Co., Ltd., Shanghai, China
Test formulation: Jiangsu Shenhua Pharmaceutical Co., Ltd., Jiangsu, China
Fig. 3 The mean (SD) concentration-time curves of
HCQ (0–60d) after administration of the test formulation
(Jiangsu Shenhua Pharmaceutical Co., Ltd., Jiangsu,
China) and reference formulation (Shanghai Zhongxi
Pharmaceutical Co., Ltd., Shanghai, China) in 20 healthy
Chinese male volunteers
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subject bioavailability of HCQ is consistent.
Therefore, according to the guideline of the
FDA, for drugs that demonstrate low intra-
subject variability in distribution and
clearance, an AUC truncated at 72 h
(AUC0–72h) can be used in place of an AUC0–t
or AUC0– [17]. This sample collection time was
adequate to ensure completion of
gastrointestinal transit (*2–3 days) of the drug
product and absorption of the drug substance.
Therefore, this study also evaluated the
bioequivalence of HCQ between a test
preparation and reference preparation in
0–72 h (AUC0–72h); the results showed that
both formulations are bioequivalent. The
results from the two studies let us confirm that
when comparing the two formulations’
bioequivalence for this kind of long half-life of
drugs such as the HCQ tablets, a bioequivalence
of 0–72 h is available to evaluate the
bioavailability.
There are some potential limitations to the
study. It was an open-label study, so it might
not have objectively addressed the safety
profiles of the test formulation. Moreover, the
data of this study were obtained from healthy
Chinese males under fasting conditions; thus,
the findings cannot be expanded to predict
therapeutic equivalence in patients in clinical
practice.
CONCLUSION
Based on the pharmacokinetics and the results
of this study, it was concluded that the test and
reference formulations of HCQ met the Chinese
criteria for assuming bioequivalence. Both
formulations were well tolerated in the
population studies. Moreover, the results of
applying a truncated AUC method in this
study showed that this method is acceptable
for estimating the relative bioavailability of
HCQ.
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